



HYPHENS PHARMA INTERNATIONAL LIMITED

**DOCMED RECEIVED S\$6M INVESTMENT
TO GROW DIGITAL HEALTHTECH**

27 MAY 2022



DISCLAIMER

This presentation has been prepared by Hyphens Pharma International Limited (the "**Company**" and, together with its subsidiaries, the "**Group**").

This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentation nor any part thereof may be (i) used or relied upon by any other party or for any other purpose; (ii) copied, photocopied, duplicated, photographed or otherwise reproduced in any form or by any means; or (iii) redistributed, passed on or otherwise disseminated or quoted, directly or indirectly, to any person either in your organisation or elsewhere. None of the Company, SAC Capital Private Limited. (the "**Sponsor**") nor any of their respective affiliates, advisors and representatives makes any representation regarding, or assumes any responsibility or liability whatsoever (in negligence or otherwise) for, the accuracy or completeness of, or any errors or omissions in, any information contained herein nor for any loss howsoever arising from any use of the content in this presentation.

By attending or viewing all or part of this presentation, you:

- i. represent and warrant that you are lawfully able to receive this presentation under the laws of the jurisdiction in which you are located and all other applicable laws;
- ii. agree to be bound by the limitations and restrictions described herein; and
- iii. agree to maintain confidentiality regarding the information disclosed in this presentation and to continue to adhere to all applicable securities and insider trading rules and laws in any jurisdiction at all times.

This presentation does not constitute, or form any part of any offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities in Singapore or any other jurisdiction nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever.

The information in this presentation is a summary only and does not purport to contain all of the information that may be required to evaluate the Company or any potential transaction. Any potential transaction could be made available to you in accordance with applicable laws and regulations, including the distribution of any required documents for such potential transaction and such documents will supersede all prior information provided to you, herein or otherwise. Information in this presentation is qualified in its entirety by reference to an offering document for any potential transaction, if it proceeds.

None of the Company, the Sponsor, and any of their respective holding companies, subsidiaries, associated undertakings, controlling persons, affiliates, and any of their respective directors, officers, partners, employees, agents, advisers or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation. It is not the intention to provide, and you may not rely on the content of this presentation as providing, a complete or comprehensive analysis of the Company's or the Group's financial or trading position or prospects. The information and opinions contained in this presentation is provided as at the date hereof (unless otherwise indicated) and are subject to change without notice. This presentation may not contain all material information concerning the Company or the Group.

The information contained in this presentation has not been independently verified. The accuracy and completeness of the information and opinions in this presentation is not guaranteed and no representation or warranty, expressed or implied, is made as to, and no reliance, in whole or in part, should be placed on the fairness, accuracy, completeness or correctness of the information, opinions or assumptions contained herein. Further, nothing in this presentation should be construed as constituting legal, business, tax or financial advice. None of the Sponsor and its subsidiaries or affiliates has independently verified, approved or endorsed the material herein.

The information in this presentation includes historical information about and relevant to the Group that should not be regarded as an indication of the future performance of the Group or the value of the shares of the Company. This presentation also contains forward-looking statements that may be identified by their use of words like "plans", "expects", "will", "anticipates", "believes", "intends", "depends", "projects", "estimates" or other words of similar meaning and that involve assumptions, risks and uncertainties. All statements that address expectations or projections about the future and all statements other than statements of historical facts included in this presentation, including, but not limited to, statements about the strategy for growth, product development, market position, expenditures, and financial results, are forward-looking statements. Such forward-looking statements are based on certain assumptions and expectations of future events regarding the Group's present and future business strategies and the environment in which the Group will operate, and must be read together with those assumptions. No assurance or guarantee is given that these assumptions and expectations are accurate or will be realised. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. These risks, uncertainties and assumptions include, without limitation, general industry and economic conditions, interest rate trends, cost of capital and capital availability, competition from other entities, shifts in customer demand, customers and partners, changes in operating expenses including employee wages, benefits and training, governmental and public policy changes and the continued availability of financing in the amounts and the terms necessary to support future business. Predictions, projections or forecasts of the economy or economic trends of the markets are not necessarily indicative of the future or likely performance of the Group. Past performance is not necessarily indicative of future performance. You are cautioned not to place undue reliance on these forward-looking statements, which are based on the Company's current view of future events. None of the Company and the Sponsor, their respective affiliates and their respective agents assumes any responsibility to amend, modify or revise any forward-looking statements, on the basis of any subsequent developments, information or events, or otherwise.

Neither this presentation nor any of its content may be used without the prior written consent of the Company and the Sponsor. Any forwarding, distribution or reproduction of the information in this presentation electronically or otherwise, in whole or in part, is unauthorised.



ABOUT DOCMED TECHNOLOGY

DocMed Technology, a wholly owned subsidiary of **Hyphens Pharma International**, was incorporated in Oct 2021 for the purpose of investment holding and development of an integrated digital healthtech platform with various healthtech solutions, to cater to various healthcare stakeholders in Singapore and the region.



OUR CORE MISSION

We are the platform that empowers doctors and healthcare stakeholders through technology and network effect to meet patient needs and optimise health outcome



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



DIGITAL ASSETS OVERVIEW



DocCentral



2001 Year of establishment

500k+ Visitor logins per annum

>51k Number of transactions annually

120+ Doctors + Telehealth Providers at launch phase

~80 Average daily e-prescriptions during launch phase

6 Key digital tools for doctors' disposal

80 Doctors for trial testing during MVP phase



LEADERSHIP



TIMOTHY CHEN

- Has been appointed CEO designate since the inception of DocMed Technology.
- A well-balanced investment management, corporate management and entrepreneurial start up experiences over the past 18 years in the various industries of investment banking, private equity/venture capital investment, and venture building of technology and media start ups.
- Will subscribe to S\$100,000 of ordinary shares in DocMed to demonstrate his commitment to the future success of the venture.



CEO

DocMed Technology



DETAILS OF SERIES A FUND RAISED



DETAILS OF TRANSACTION

- **Lead Investor**
 - Metro ARC Investment Pte Ltd, a wholly owned subsidiary of Metro Holdings Ltd.
- **Investment into DocMed Technology**
- **Fund Raised**
 - S\$6 million for a 10%
- **Instrument**
 - Preference Share
- **Post Money Valuation of DocMed Technology**
 - S\$60m



RATIONALE OF TRANSACTION



RATIONALE OF TRANSACTION

- To consolidate all digital assets of the Hyphens Group under DocMed to develop an integrated digital healthtech platform, including existing assets of POM (*Singapore's leading B2B digital hypermart*) and WellAway Pharmacy, both of which are operated by Pan-Malayan Pharmaceuticals.
- To unlock the value of the Group's medical hypermart and digital business segment. This also includes the Group's wholesale business for pharmaceuticals and medical supplies in Singapore and its B2B e-commerce platform, as well as WellAway, which is Singapore's first and only HSA-registered e-pharmacy.
- The capital injection shall be utilised to further DocMed's growth plans, which includes developing an integrated healthtech platform, incorporating various healthtech solutions to cater to healthcare stakeholders in Singapore and the Asia Pacific region, as well as for working capital purpose.
- The parent company of lead investor, Metro Holdings, is an established and reputable corporate, with regional portfolio presence that DocMed will be able to leverage on to bring its business to the next level.




USAGE OF FUNDS

- To develop an integrated healthtech platform
- Recruitment of manpower talent in digital and operational expertise across the region
- Expansion of existing key digital assets in countries, such as Malaysia, Vietnam and other ASEAN countries

Expected Runway: 24 Months


BREAKDOWN IN \$MIL



POST DEAL RESTRUCTURING



POST DEAL COMPLETION STRUCTURE



FINANCIAL EFFECTS

	Pre-Deal	Post-Deal ⁽¹⁾
NTA of the Group as at 31 December 2021 (S\$'000)	34,483	39,713
Number of issued shares in the share capital of the Company ('000)	308,776	308,776
NTA per share (S\$ cents)	11.17	12.86
FY2021 profit attributable to the shareholders of the Company (S\$'000)	6,846	6,793
Weighted average number of issued shares in the share capital of the Company ('000)	301,707	301,707
EPS FY2021 (S\$ cents)	2.27	2.25

(1) Financial effects on NTA per share is based on assumption that transaction had been fully effected on 31 December 2021

(2) Financial effects on EPS is based on assumption that transaction had been fully effected on 1 January 2021





Hyphens Pharma International Limited (SGX: 1J5)
16 Tai Seng Street, Level 4, Singapore 534138
www.hyphensgroup.com

in | Follow us on LinkedIn